The challenges of diagnosing osteoporosis and the limitations of currently available tools

被引:152
作者
Palak Choksi
Karl J. Jepsen
Gregory A. Clines
机构
[1] University of Michigan,Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine
[2] University of Michigan,Departments of Orthopaedic Surgery and Biomedical Engineering
[3] Endocrinology Section,undefined
[4] Ann Arbor VA Medical Center,undefined
来源
Clinical Diabetes and Endocrinology | / 4卷 / 1期
关键词
Osteoporosis; Dual X-ray absorptiometry; Peripheral quantitative computed tomography; Skeletal fracture; Skeletal biomechanics; Bisphosphonates; Denosumab; Teriparatide; Romosozumab;
D O I
10.1186/s40842-018-0062-7
中图分类号
学科分类号
摘要
Dual-energy X-ray absorptiometry (DXA) was the first imaging tool widely utilized by clinicians to assess fracture risk, especially in postmenopausal women. The development of DXA nearly coincided with the availability of effective osteoporosis medications. Although osteoporosis in adults is diagnosed based on a T-score equal to or below − 2.5 SD, most individuals who sustain fragility fractures are above this arbitrary cutoff. This incongruity poses a challenge to clinicians to identify patients who may benefit from osteoporosis treatments. DXA scanners generate 2 dimensional images of complex 3 dimensional structures, and report bone density as the quotient of the bone mineral content divided by the bone area. An obvious pitfall of this method is that a larger bone will convey superior strength, but may in fact have the same bone density as a smaller bone. Other imaging modalities are available such as peripheral quantitative CT, but are largely research tools. Current osteoporosis medications increase bone density and reduce fracture risk but the mechanisms of these actions vary. Anti-resorptive medications (bisphosphonates and denosumab) primarily increase endocortical bone by bolstering mineralization of endosteal resorption pits and thereby increase cortical thickness and reduce cortical porosity. Anabolic medications (teriparatide and abaloparatide) increase the periosteal and endosteal perimeters without large changes in cortical thickness resulting in a larger more structurally sound bone. Because of the differences in the mechanisms of the various drugs, there are likely benefits of selecting a treatment based on a patient’s unique bone structure and pattern of bone loss. This review retreats to basic principles in order to advance clinical management of fragility fractures by examining how skeletal biomechanics, size, shape, and ultra-structural properties are the ultimate predictors of bone strength. Accurate measurement of these skeletal parameters through the development of better imaging scanners is critical to advancing fracture risk assessment and informing clinicians on the best treatment strategy. With this information, a “treat to target” approach could be employed to tailor current and future therapies to each patient’s unique skeletal characteristics.
引用
收藏
相关论文
共 654 条
[1]  
Wahner HW(1988)Comparison of dual-energy x-ray absorptiometry and dual photon absorptiometry for bone mineral measurements of the lumbar spine Mayo Clin Proc 63 1075-1084
[2]  
Dunn WL(1994)Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group Osteoporos Int 4 368-381
[3]  
Brown ML(2006)Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38 694-700
[4]  
Morin RL(2008)A reference standard for the description of osteoporosis Bone 42 467-475
[5]  
Riggs BL(1990)Incidence of fractures in a geographically defined population J Epidemiol Community Health 44 241-245
[6]  
Kanis JA(1999)Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878-882
[7]  
Sanders KM(2002)Survival and potential years of life lost after hip fracture in men and age-matched women Osteoporos Int 13 731-737
[8]  
Nicholson GC(2005)Identification of osteopenic women at high risk of fracture: the OFELY study J Bone Miner Res 20 1813-1819
[9]  
Watts JJ(2004)Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study Bone 34 195-202
[10]  
Pasco JA(2010)Genetics of osteoporosis Endocr Rev 31 629-662